Gail Murphy

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

K. C. Morris, Michele R. Shaw, Mohammed Salah Ibrahim, 2023, The Lancet.

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone–insulin‐like growth factor I axis in growth hormone–deficient children

J. Svensson, E. Codner, F. Cassorla, 2001, Clinical pharmacology and therapeutics.

Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males

S. Mohan, C. Ohlsson, J. Svensson, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

L. Lönn, L. Sjöström, J. Svensson, 1998, The Journal of clinical endocrinology and metabolism.

Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.

M. Thorner, G. Murphy, D. Krupa, 1997, The Journal of clinical endocrinology and metabolism.

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

C. Lines, J. Chodakewitz, Junshui Ma, 2013, Sleep.